Article Text

Download PDFPDF

P151 Demyelination with autoimmune features (DAF) – results from the attikon cohort
  1. Dionysis Nikolopoulos1,
  2. Antonis Fanouriakis1,
  3. Dimitris Kitsos2,
  4. Matilda Papathanasiou3,
  5. Maria Chondrogianni2,
  6. Panagiotis Garatziotis1,
  7. Antigone Pieta1,
  8. Triantafyllos Doskas4,
  9. Konstantinos Voumvourakis2 and
  10. Dimitrios Boumpas1
  1. 1Rheumatology and Clinical Immunology Unit, ‘Attikon’ University Hospital, Athens
  2. 2Dept. of Neurology, ‘Attikon’ University Hospital, Athens
  3. 3Dept. of Radiology, ‘Attikon’ University Hospital, Athens
  4. 4Dept. of Neurology, Athens Naval Hospital, Athens, Greece


Background Patients with demyelination may manifest features of autoimmune rheumatic diseases. We evaluated patients presenting with a demyelinating syndrome and clinical or autoantibody evidence for an underlying connective tissue disease (CTD).

Methods Patients with clinical and/or imaging evidence of demyelination referred to a rheumatology unit. Diagnoses of multiple sclerosis (MS) and systemic lupus erythematosus (SLE) were made according to McDonald and SLICC classification criteria, respectively. Patients with features of CTD not fulfilling criteria for a specific disease were labelled as demyelination with autoimmune features (DAF). Demographics, clinical/serological/imaging data and treatments were recorded at every visit, following multidisciplinary evaluation (neurology, rheumatology, neuroimaging).

Results Sixty-five patients (n=65) were included in the study [93.8% female, mean (SD) age at first demyelinating episode 37.3 (11.8) and median (IQR) duration to last follow-up 4 (7) years]. Rheumatologic clinical manifestations and autoantibodies of all patients are summarized in table 1. Fifty-two patients had lesions in the brain (80%), 32 in the spinal cord (49.2%) and 5 in the brainstem (7.7%), while 17 developed optic neuritis (26.2%). Among the 65 patients, at last follow-up, 32 patients (49.2%) had fulfilled diagnostic criteria for MS with 11 patients (34.4)) diagnosed as overlap between SLE and MS and 16 patients (50%) had CTD features not fulfilling criteria for any known CTD. Of patients with demyelinating syndrome not fulfilling criteria for MS (n=33), 7 patients (21.2%) had SLE while 22 patients (66.7%) were classified as DAF. Most common features of DAF patients were ANA, arthritis and mucocutaneous features of SLE.

Abstract P151 Table 1

Clinical and serological characteristics

Conclusions Among patients with demyelination and features of CTD a significant number of patients do not fulfil criteria for either MS or SLE. These patients exhibit lupus-like autoimmune features and may represent a distinct group of patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.